
Zai Lab Limited – NASDAQ:ZLAB
Zai Lab Limited stock price today
Zai Lab Limited stock price monthly change
Zai Lab Limited stock price quarterly change
Zai Lab Limited stock price yearly change
Zai Lab Limited key metrics
Market Cap | 2.89B |
Enterprise value | 2.54B |
P/E | -8.19 |
EV/Sales | 11.84 |
EV/EBITDA | -5.92 |
Price/Sales | 16.44 |
Price/Book | 3.38 |
PEG ratio | -0.16 |
EPS | -3.49 |
Revenue | 291.07M |
EBITDA | -320.71M |
Income | -338.94M |
Revenue Q/Q | 38.77% |
Revenue Y/Y | 25.94% |
Profit margin | -206.14% |
Oper. margin | -188.04% |
Gross margin | 65.58% |
EBIT margin | -188.04% |
EBITDA margin | -110.18% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZai Lab Limited stock price history
Zai Lab Limited stock forecast
Zai Lab Limited financial statements
Jun 2023 | 68.86M | -120.89M | -175.56% |
---|---|---|---|
Sep 2023 | 69.22M | -69.15M | -99.89% |
Dec 2023 | 65.83M | -95.42M | -144.96% |
Mar 2024 | 87.14M | -53.47M | -61.36% |
2025 | 596.51M | -157.33M | -26.38% |
---|---|---|---|
2026 | 942.82M | 70.69M | 7.5% |
2027 | 1.40B | 143.17M | 10.21% |
2028 | 1.77B | 327.17M | 18.39% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 1106373000 | 174.05M | 15.73% |
---|---|---|---|
Sep 2023 | 1043694000 | 162.71M | 15.59% |
Dec 2023 | 1036295000 | 240.17M | 23.18% |
Mar 2024 | 988437000 | 226.26M | 22.89% |
Jun 2023 | -58.70M | 42.70M | -1.49M |
---|---|---|---|
Sep 2023 | -55.27M | -13.98M | -1.44M |
Dec 2023 | -14.91M | 14.45M | 393K |
Mar 2024 | -90.10M | 3.29M | 47.54M |
Zai Lab Limited alternative data
Aug 2023 | 2,036 |
---|---|
Sep 2023 | 2,036 |
Oct 2023 | 2,036 |
Nov 2023 | 2,036 |
Dec 2023 | 2,036 |
Jan 2024 | 2,036 |
Feb 2024 | 2,036 |
Mar 2024 | 2,175 |
Apr 2024 | 2,175 |
May 2024 | 2,175 |
Jun 2024 | 2,175 |
Jul 2024 | 2,175 |
Zai Lab Limited other data
Period | Buy | Sel |
---|---|---|
Nov 2023 | 5000 | 165 |
Dec 2023 | 4000 | 0 |
Jan 2024 | 0 | 37349 |
Mar 2024 | 3000 | 12544 |
Apr 2024 | 0 | 17098 |
May 2024 | 3000 | 10000 |
Jun 2024 | 0 | 38586 |
Jul 2024 | 0 | 17410 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | LIS WILLIAM director | American Depositary Shares | 10,297 | $17.31 | $178,282 | ||
Sale | LIS WILLIAM director | American Depositary Shares | 100 | $18.04 | $1,804 | ||
Sale | DU YING director, officer.. | American Depositary Shares | 7,013 | $17.48 | $122,573 | ||
Option | DU YING director, officer.. | American Depositary Shares | 17,970 | N/A | N/A | ||
Option | DU YING director, officer.. | Restricted Share Units | 17,970 | N/A | N/A | ||
Sale | REINHART HARALD officer: See Remarks | American Depositary Shares | 7,431 | $17.9 | $133,022 | ||
Sale | DU YING director, officer.. | American Depositary Shares | 23,939 | $17.9 | $428,532 | ||
Sale | EDMONDSON FRAZOR TITUS III officer: Chief Le.. | American Depositary Shares | 5,062 | $17.9 | $90,615 | ||
Sale | CHEN YAJING officer: Chief Financial Officer | American Depositary Shares | 2,154 | $17.9 | $38,559 | ||
Option | REINHART HARALD officer: See Remarks | American Depositary Shares | 18,250 | N/A | N/A |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Ying Du (1966) Founder, Chairperson & Chief Executive Officer | $1,380,000 |
Mr. Frazor Titus Edmondson III (1966) Chief Legal Officer & Corporation Sec. | $707,300 |
Mr. Tao Fu (1972) Chief Strategy Officer | $649,770 |
Mr. Ki Chul Cho (1978) Chief Financial Officer | $624,960 |
Dr. Alan Bart Sandler M.D. (1957) Pres & Head of Global Devel. in Oncology | $545,000 |
Zai Lab Limited: Banking On Chinese Pharma Growth
Bulls In A China Shop: 5 Chinese Stocks To Ride Out The Trade War
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
A Risky Bet: Zai Lab's Uncertain Future
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Zai Lab Stock: De-Risking Through Market Tapping
Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments
Zai Lab: LUNAR Trial Paves Way For New Therapies
-
What's the price of Zai Lab Limited stock today?
One share of Zai Lab Limited stock can currently be purchased for approximately $35.55.
-
When is Zai Lab Limited's next earnings date?
Unfortunately, Zai Lab Limited's (ZLAB) next earnings date is currently unknown.
-
Does Zai Lab Limited pay dividends?
No, Zai Lab Limited does not pay dividends.
-
How much money does Zai Lab Limited make?
Zai Lab Limited has a market capitalization of 2.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.03% to 266.72M US dollars.
-
What is Zai Lab Limited's stock symbol?
Zai Lab Limited is traded on the NASDAQ under the ticker symbol "ZLAB".
-
What is Zai Lab Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Zai Lab Limited?
Shares of Zai Lab Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Zai Lab Limited's key executives?
Zai Lab Limited's management team includes the following people:
- Dr. Ying Du Founder, Chairperson & Chief Executive Officer(age: 59, pay: $1,380,000)
- Mr. Frazor Titus Edmondson III Chief Legal Officer & Corporation Sec.(age: 59, pay: $707,300)
- Mr. Tao Fu Chief Strategy Officer(age: 53, pay: $649,770)
- Mr. Ki Chul Cho Chief Financial Officer(age: 47, pay: $624,960)
- Dr. Alan Bart Sandler M.D. Pres & Head of Global Devel. in Oncology(age: 68, pay: $545,000)
-
Is Zai Lab Limited founder-led company?
Yes, Zai Lab Limited is a company led by its founder Dr. Ying Du.
-
How many employees does Zai Lab Limited have?
As Jul 2024, Zai Lab Limited employs 2,175 workers.
-
When Zai Lab Limited went public?
Zai Lab Limited is publicly traded company for more then 7 years since IPO on 20 Sep 2017.
-
What is Zai Lab Limited's official website?
The official website for Zai Lab Limited is zailaboratory.com.
-
How can i contact Zai Lab Limited?
Zai Lab Limited can be reached via phone at +86 21 6163 2588.
Zai Lab Limited company profile:

Zai Lab Limited
zailaboratory.comNASDAQ
2,175
Biotechnology
Healthcare
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Shanghai, 201210
CIK: 0001704292
ISIN: US98887Q1040
CUSIP: 98887Q104